¼¼°èÀÇ È£Èí±â Áø´Ü ½ÃÀå
Respiratory Diagnostics
»óǰÄÚµå : 1546151
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 174 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,301,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,905,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

È£Èí±â Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 98¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 72¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â È£Èí±â Áø´Ü ¼¼°è ½ÃÀåÀº 2023-2030³â°£ CAGR 4.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 98¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±â°è °Ë»ç´Â CAGR 4.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 58¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿µ»ó °Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 5.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 20¾ï ´Þ·¯, Áß±¹Àº CAGR7.5%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ È£Èí±â Áø´Ü ½ÃÀåÀº 2023³â¿¡ 20¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 21¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¾î ºÐ¼® ±â°£ÀÎ 2023-2030³â°£ CAGR Àº 7.5%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.3%¿Í 3.7%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è È£Èí±â Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

È£Èí±â Áø´Ü: Æó ÁúȯÀ» ´õ Àß °¨ÁöÇÒ ¼ö ÀÖ´Ù

È£Èí±â Áø´ÜÀº º¸´Ù Á¤È®ÇÏ°í ºñħ½ÀÀûÀÌ¸ç ½Å¼ÓÇÑ °Ë»ç ¹æ¹ýÀ» Á¦°øÇÔÀ¸·Î½á Æó ÁúȯÀÇ ¹ß°ß°ú °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áø´Ü ¹æ¹ý¿¡´Â Æó ±â´ÉÀ» Æò°¡ÇÏ°í °áÇÙ, õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó °¨¿°°ú °°Àº ÁúȯÀ» °¨ÁöÇϱâ À§ÇØ ÆóȰ·® ÃøÁ¤, Ç÷¾×°¡½º ºÐ¼®, ¿µ»ó ±â¼ú µî ´Ù¾çÇÑ °Ë»ç°¡ Æ÷ÇԵ˴ϴÙ. ´ëºÎºÐÀÇ È£Èí±â ÁúȯÀº ¹æÄ¡ÇÒ °æ¿ì ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö Àֱ⠶§¹®¿¡ È¿°úÀûÀÎ Ä¡·á¿Í °ü¸®¸¦ À§Çؼ­´Â Á¶±â ¹ß°ßÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÇ·áÁøÀº È£Èí±â ÁúȯÀ» º¸´Ù Á¤È®ÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖ°Ô µÇ¾î ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú ¹ßÀüÀÌ È£Èí±â Áø´ÜÀ» Çâ»ó½Ã۰í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº È£Èí±â Áø´ÜÀÇ ±â´ÉÀ» Å©°Ô Çâ»ó½ÃÄÑ ´õ Á¤È®Çϰí, ´õ Á¢±ÙÇϱ⠽±°í, ´õ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. °íÇØ»óµµ ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(HRCT) ¹× ÀÚ±â°ø¸í¿µ»ó(MRI)°ú °°Àº ¿µ»ó±â¼úÀÇ Çõ½ÅÀº ÆóÀÇ ±¸Á¶¸¦ »ó¼¼ÇÏ°Ô ½Ã°¢È­ÇÏ¿© Ç¥ÁØ ¿¢½º·¹À̷δ º¼ ¼ö ¾ø´Â Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¶ÇÇÑ, ÈÞ´ë¿ë ÆóȰ·®°è ¹× ¸Æ¹Ú »ê¼Ò ÃøÁ¤±â¿Í °°Àº ÈÞ´ë¿ë ÇöÀå Áø´Ü ±â±âÀÇ °³¹ß·Î ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü´Â 1Â÷ Áø·á¼Ò ¹× ȯÀÚÀÇ Áý°ú °°Àº ´Ù¾çÇÑ È¯°æ¿¡¼­ ½±°Ô °Ë»çÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) ¹× Â÷¼¼´ë ¿°±â¼­¿­ºÐ¼®(NGS)À» Æ÷ÇÔÇÑ ºÐÀÚÁø´ÜÀÇ ¹ßÀüÀ¸·Î È£Èí±â Áúȯ°ú °ü·ÃµÈ ƯÁ¤ º´¿øÃ¼ ¹× À¯ÀüÀÚ ¸¶Ä¿¸¦ °ËÃâÇÏ´Â ´É·Âµµ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº È£Èí±â Áø´ÜÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ°í Æó °Ç°­ »óŸ¦ º¸´Ù Á¾ÇÕÀûÀ̰í Á¤È®ÇÏ°Ô Æò°¡ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

È£Èí±â Áø´ÜÀÇ ÁÖ¿ä ¿ëµµ¿Í ÀåÁ¡Àº ¹«¾ùÀΰ¡?

È£Èí±â Áø´ÜÀº Æó ±â´É Æò°¡, È£Èí±â Áúȯ Áø´Ü, Ä¡·á È¿°ú ¸ð´ÏÅ͸µ µî ´Ù¾çÇÑ ÀÓ»ó ÇöÀå¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. 1Â÷ Áø·á¿¡¼­ ÆóȰ·®°ú ±â·ù¸¦ ÃøÁ¤ÇÏ´Â ÀϹÝÀûÀÎ Áø´Ü µµ±¸ÀÎ ÆóȰ·® ÃøÁ¤Àº õ½Ä ¹× COPD¿Í °°Àº Áúº´À» Áø´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. º´¿ø¿¡¼­´Â Ç÷¾×°¡½º ºÐ¼® ¹× HRCT ½ºÄµ°ú °°Àº °í±Þ °Ë»ç°¡ È£Èí±â ÁúȯÀÇ ½É°¢¼ºÀ» Æò°¡Çϰí Ä¡·á ¹æÄ§À» °áÁ¤ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. È£Èí±â °Ë»ç¿¡¼­ ºÐÀÚÁø´ÜÀÇ »ç¿ëÀº ƯÈ÷ È£Èí±â °¨¿°À» À¯¹ßÇϴ ƯÁ¤ º´¿øÃ¼¸¦ ½Äº°Çϰí Ç¥Àû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â µ¥ ÀÖ¾î Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. È£Èí±â Áø´ÜÀÇ ÁÖ¿ä ÀåÁ¡Àº Æó ÁúȯÀÇ Á¶±â ¹ß°ß, Áø´Ü Á¤È®µµ Çâ»ó, Áúº´ ÁøÇà ¹× Ä¡·á °á°ú ¸ð´ÏÅ͸µ Çâ»ó µîÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡À¸·Î ÀÎÇØ È£Èí±â Áø´ÜÀº ´õ ³ªÀº ȯÀÚ Ä¡·á¿Í Áúº´ °ü¸®¸¦ Áö¿øÇÏ´Â Çö´ë ÀÇ·áÀÇ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

È£Èí±â Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

È£Èí±â Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. õ½Ä, COPD, Æó °¨¿°°ú °°Àº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Áß¿äÇÑ ÃËÁø¿äÀÎÀ̸ç, ÀÌ·¯ÇÑ ÁúȯÀº Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ƯÈ÷ ¿µ»óÁø´Ü, ºÐÀÚÁø´Ü, ÇöÀåÁø´Ü(point-of-care) ±â±â µîÀÇ ±â¼ú ¹ßÀüÀº È£Èí±â Áø´ÜÀÇ ±â´É°ú Á¢±Ù¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. È£Èí±â ÁúȯÀÇ Á¶±â ¹ß°ß°ú Á¶±â °ü¸®ÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¶±â °³ÀÔÀ» ÅëÇØ ÇÕº´ÁõÀ» ¿¹¹æÇϰí ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Ù´Â ÀνÄÀÌ È®»êµÇ¸é¼­ ÀÌ·¯ÇÑ Áø´Ü ¾àǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Äڷγª19 ÆÒµ¥¹ÍÀÇ Áö¼ÓÀûÀÎ ¿µÇâÀº È¿°úÀûÀΠȣÈí±â Áø´ÜÀÇ Çʿ伺À» °­Á¶Çϸç ÀÌ ºÐ¾ß¿¡ ´ëÇÑ ´õ ¸¹Àº ÅõÀÚ¿Í Çõ½ÅÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ÀÇ·á ±â¼úÀÇ Áö¼ÓÀûÀÎ ¹ßÀü°ú ÇÔ²² È£Èí±â Áø´Ü ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñ 43°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Respiratory Diagnostics Market to Reach US$9.8 Billion by 2030

The global market for Respiratory Diagnostics estimated at US$7.2 Billion in the year 2023, is expected to reach US$9.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Mechanical Tests, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$5.8 Billion by the end of the analysis period. Growth in the Imaging Tests segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 7.5% CAGR

The Respiratory Diagnostics market in the U.S. is estimated at US$2.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Respiratory Diagnostics Market - Key Trends and Drivers Summarized

Respiratory Diagnostics: Advancing the Detection of Lung Diseases

Respiratory diagnostics are revolutionizing the detection and management of lung diseases by providing more accurate, non-invasive, and rapid testing methods. These diagnostics encompass a range of tests, including spirometry, blood gas analysis, and imaging techniques, that assess lung function and detect conditions such as tuberculosis, asthma, chronic obstructive pulmonary disease (COPD), and lung infections. Early detection of respiratory diseases is crucial for effective treatment and management, as many of these conditions can lead to severe complications if left untreated. With advancements in diagnostic technology, healthcare providers can now diagnose respiratory conditions with greater precision, leading to improved patient outcomes and a higher quality of life for those affected.

What Technological Advancements Are Enhancing Respiratory Diagnostics?

Technological advancements are significantly enhancing the capabilities of respiratory diagnostics, making them more accurate, accessible, and user-friendly. Innovations in imaging technology, such as high-resolution computed tomography (HRCT) and magnetic resonance imaging (MRI), allow for detailed visualization of lung structures, enabling the early detection of diseases that may not be apparent on standard X-rays. Additionally, the development of portable and point-of-care diagnostic devices, such as handheld spirometers and pulse oximeters, has made it easier for healthcare providers to conduct tests in various settings, including primary care offices and patient homes. Advances in molecular diagnostics, including polymerase chain reaction (PCR) and next-generation sequencing (NGS), have also improved the ability to detect specific pathogens and genetic markers associated with respiratory diseases. These technological innovations are driving the adoption of respiratory diagnostics, providing more comprehensive and accurate assessments of lung health.

What Are the Key Applications and Benefits of Respiratory Diagnostics?

Respiratory diagnostics are used in a wide range of clinical settings to assess lung function, diagnose respiratory diseases, and monitor treatment effectiveness. In primary care, spirometry is a common diagnostic tool used to measure lung capacity and airflow, helping to diagnose conditions like asthma and COPD. In hospitals, more advanced tests such as blood gas analysis and HRCT scans are used to assess the severity of respiratory conditions and guide treatment decisions. The use of molecular diagnostics in respiratory testing has become increasingly important, particularly in identifying the specific pathogens causing respiratory infections, enabling targeted treatment. The primary benefits of respiratory diagnostics include early detection of lung diseases, improved accuracy in diagnosis, and better monitoring of disease progression and treatment outcomes. These advantages make respiratory diagnostics a critical component of modern healthcare, supporting better patient care and disease management.

What Factors Are Driving the Growth in the Respiratory Diagnostics Market?

The growth in the Respiratory Diagnostics market is driven by several factors. The increasing prevalence of respiratory diseases, such as asthma, COPD, and lung infections, is a significant driver, as these conditions create a growing demand for accurate and reliable diagnostic tools. Technological advancements, particularly in imaging, molecular diagnostics, and point-of-care devices, are also propelling market growth by enhancing the capabilities and accessibility of respiratory diagnostics. The rising awareness of the importance of early detection and management of respiratory conditions is further boosting demand for these diagnostics, as early intervention can prevent complications and improve patient outcomes. Additionally, the ongoing impact of the COVID-19 pandemic has highlighted the critical need for effective respiratory diagnostics, driving further investment and innovation in this field. These factors, combined with the continuous advancement of medical technology, are driving the sustained growth of the Respiratory Diagnostics market.

Select Competitors (Total 43 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â